Leading the Way in Life Science Technologies

GEN Exclusives

More »

Wall Street BioBeat

More »
Apr 1, 2010 (Vol. 30, No. 7)

IP Position Critical to Biotech Investment

Looming Battle over Gene Patenting Could Jeopardize Medical Advances

  • Takeaways: The Case for Gene Patents

    • Gene patents are the foundation of the biotech industry and precluding them would halt forward progress.
    • The patent system promotes innovation and stimulates investment in R&D.
    • If there were no exclusive rights in the final product, there would be
      little incentive to invest time and money into developing it.
    • Without the incentives offered by the issuance of patents, the industry and, ultimately, patients would suffer.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »